Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept plus mFOLFOX6 in untreated metastatic colorectal cancer
NCT01652196Phase 2Completed
- Sponsor
- Hays
- Start
- Nov 2012
- Primary completion
- Aug 2019
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label trial of aflibercept in colorectal cancer (CRC), sponsored by Hays. Primary endpoint: Proportion of Patients Alive and Progression-free at 15 Months. Started Nov 2012; status: completed.
02
Drugs
aflibercept
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT01652196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01652196.